Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RecruitingPhase 2Healthy volunteers welcome
Who can join
Ages 40 to 60 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3 months * cocounut allergy
About the study
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
What is being tested
- Hemp-derived cannabinoids (drug)
- Placebo (drug)
Sponsor: Washington State University · Participants: 104 · Started: Feb 11, 2026
Contact the study team
- Carrie Cuttler, PhD · Phone: (509) 592-0151
Official record on ClinicalTrials.gov — NCT07393672
Locations in the U.S.
| Washington | Washington State University, Dept of Psychology, Pullman |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.